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The ability of gamma interferon (IFN-y) to affect cutaneous 
collagen synthesis in vivo was examined in a murine wound-
ing model. Reproducible areas of full-thickness skin necrosis 
were produced by argon laser radiation. Mice received re-
combinant murine IFN-y (rMuIFN-y) (8.7 X 103 units/hr) 
over 14 d via osmotic pumps implanted subcutaneously or 
intraperitoneally. At 14 and 21 d after wounding, there was 
less fibrous tissue in healing scars of treated animals as deter-
mined by light and transmission electron microscopy. Asso-
ciated with the decrease in connective tissue was an increase 
in the acid mucopolysaccharide content of healing scars, 
which was largely hyaluronate. Quantitative image analysis 
of electron micrographs confirmed that less collagen was 
present in healing scars of animals receiving rMuIFN-y. The 
mean cross-sectional area of collagen fibers was smaller in 
C ollagen is the major fibrous protein in connective tissue and is the primary structural component of all organs and tissues. The balance between synthesis and degradation of collagen is maintained in tight control but is transiently altered in repair processes 
such as wound healing [1]. Abnormalities in collagen turnover may 
lead to pathologic fibrosis of the skin in various disease states such as 
scleroderma [2], morphea [3], and keloid formation [4,5]. Previous 
studies have demonstrated that products of inflammatory cells may 
function in the regulation of collagen synthesis and degradation [6]. 
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specimens from treated mice, but no difference was seen in 
the size of collagen fibrils. The time required to obtain full 
skin closure was also delayed 23% - 27% in treated animals. 
Using this injury model, we also found that rMuIFN-y sig-
nificantly reduced the degree of perilesional erythema sur-
rounding the laser injury sites and, in the first 6 dafter 
wounding, the degree of polymorphonuclear infiltrate 
present histologically at lesional sites. Indeed, rMuIFN -y also 
decreased the cutaneous accumulation of neutrophils in-
duced by known proinflammatory mediators, such as inter-
leukin 1 and activated serum. Thus, systemically adminis-
tered IFN-y not only down-regulates collagen synthesis in 
the skin but also modulates in a previously unrecognized 
manner: neutrophil accumulation at sites of tissue injury in 
vivo.] Invest Dermatol 93:18-27, 1989 
as demonstrated in cell culture systems [7 - 14]. Interleukin- 1 
(IL-l), a cytokine produced by a variety of cell types, increases 
collagen and fibronectin synthesis by synovial and dermal fibro-
blasts and chondrocytes [14,15] as well as by murine mammary 
epithelial cells [16). In contrast, the Iymphokine gamma interferon 
(IFN-y) inhibits types I and III collagen and fibronectin synthesis by 
dermal and synovial fibroblasts and type II collagen synthesis by 
chondrocytes in a dose-dependent manner [17 - 20]. This inhibition 
of collagen synthesis is associated with decreased levels of cellular 
messenger RNA (mRNA) for these proteins [20 -22). We have 
recently reported that recombinant murine IFN-y (rMuIFN-y) de-
creases collagen synthesis in a model of fibrous tissue formation in 
reaction to a subcutaneously implanted foreign body [23]. In addi-
tion, the development of bleomycin-induced pulmonary fibrosis in 
mice is also decreased by administration of IFN-y [24]. 
In addition to its effect on collagen synthesis, IFN-y influences 
the phenotype and function of a variety of cells in vitro and in vivo. 
The expression of major histocompatibility complex class II anti-
gens on many normal and transformed cells is enhanced or induced 
by IFN-y both in vitro and in vivo [18,25,26] . IFN-y also alters 
several effector functions of macrophages. It increases their hydro-
gen peroxide releasing capacity and anti-protozoal activity and en-
hances their ability to kill tumor cells [27 - 30]. 
In order to further examine the physiologic and pharmacologic 
relevance of our previous in vitro and in vivo observations on the 
regulation of collagen synthesis by IFN-y, we developed a simple 
and reproducible skin wounding model to examine the potential 
influence of IFN-y on new collagen synthesis in normal wound 
repair. We found that rMuIFN-y retarded the healing process of 
skin wounds and decreased the collagen content of resulting scar 
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tissue. These changes were associated with the unexpected finding 
that administration of rMuIFN-y inhibited the inflammatory re-
sponse to wounding as assessed by decreased perilesional erythema 
and acute inflammatory infiltrate. This ability of systemically ad-
ministered IFN-y to decrease acute inflammation in vivo was fur-
ther demonstrated using defined mediators of inflammation such as 
IL-l and activated serum. 
MATERIALS AND METHODS 
Animals Female CAFI (BALB/c X A/]) and A/J mice were ob-
tained from the Jackson Laboratory (Bar Harbor, ME). The animals 
were 8 to 12 weeks old at the start of each experiment, and the age of 
the animals did not vary by more than 2 weeks within anyone 
experiment. The mice had free access to Purina Mouse Chow (Ral-
ston Purina Company, St. Louis, MO) and chlorinated water, and 
were housed in a facility where ambient light was regulated on a 
12-h light/dark cycle. 
Cytokines Biologically active, rMuIFN-y (specific activity 5.2 X 
107 units per mg) was kindly provided by Genentech, Inc. (South 
San Francisco, CA) and was stored at 4 ° C in concentrated form and 
diluted immediately before use. Units of activity were determined 
by a cytopathic effect inhibition assay using L929 murine fibroblasts 
challenged with encephalomyocarditis virus. Titers were expressed 
in international units on the basis of the murine IFN-a/p research 
reference standard G002-904-511. This preparation contained less 
than 0.25 EU /ml by theLimulus amoebocyte lysate test at a concen-
tration of 1.74 X 107 units/ml, where 1 EU is the amount of Limu-
Ius amoebocyte lysate reactive material in 2 ng of U .S. Pharmacopia 
reference standard endotoxin (Escherichia coli lipopolysaccharide) . 
Recombinant human IL-l alpha (rHuIL-la) was the generous 
gift of Hoffman-LaRoche, Inc. (Nutley, NJ). This material exhibits 
a specific activity of approximately 6 X 106 units per mg, with 1 
unit producing 50% of the maximal response in the thymocyte 
costimulator assay [31] . 
Serum Activation Activated mouse serum was prepared by boil-
ing Zymosan A (Sigma Chemical Co., St. Louis, MO) in normal 
saline for 15 min, washing it twice with normal saline, and then 
adding it to serum at a concentration of 5 mg/ml. After incubation 
at 37°C for 1 h, centrifugation at 2,000 g was performed, and the 
supernatant was decanted and used immediately. 
Skin Wounding Mice were anesthetized by intrape~itoneal injec-
tion of 0.1 ml/10 gram body weight of a 3.6% solution of c~loral 
hydrate. The dorsal surfaces of the mice were shaved and cheffilcally 
depilated (Neet, Whitehall Laboratories, New York, ~Y). Full-
thickness thermal wounds were induced on the dorsal skin of anes-
thetized mice by a pulse of argon laser radiation. The optic~1 ~nd 
thermal distributions in murine skin from such argon laser radIation 
has been described [32] . The argon-ion laser (Model INN OVA 
100-20, Coherent, Palo Alto, CA) was operated in a single wave-
length mode at 488 nm. The beam was transmitted through. 4 f~et 
of 1 mm diameter optical fiber and focused throug.h a 10 X obJ~ctl~e 
lens to yield a 3-mm diameter image of the fiber up on the antmal s 
back. This method of optical delivery produces a very flat field, thus 
avoiding hot spots. The animal was positioned 6.4 cm from the 
objective lens against a plate with a 0.5 cm diameter hole for expo-
sure to the laser. The power transmitted out of the objective lens was 
measured with a pyroelectric power meter. (C~her~nt, . Palo ~lto, 
CA). Four watts were delivered onto the skll1 SIte, Yleldmg an Irra-
diance of 57 W /cm2 over the 3-mm diamete~ exposure site. -r:he 
laser light was delivered in 3-s pulses by . a timed shu~ter .whlch 
reliably produced visible thermal coagulatlon of the skin sIte and 
controlled, reproducible wounds. The baseline skin temperature 
was 29° ± 1°C, as measured by a thermocouple. 
Pump Implantation Small osmotic pum.l's were obtained from 
Alza Corp. (Model 2002, Palo Alto, CA) [33]. These cylindrical 
pumps, when loaded and assembled, me~sured 3.0 cm along the 
long axis and 0.7 cm in diameter. They delIver 0.5 .ul/h for 14 d. In 
one experiment, pumps delivering 1.0 .ul/h for 7 d (Model 2001) 
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were employed. They have an outer membrane of cellulose ester 
and have a cap at the exit port composed of ethylene co-polymer. 
Pumps were loaded with rMuIFN-y in phosphate-buffered saline 
(PBS) containing 0.1 % normal mouse serum (diluent) or with di-
luent alo~e. Under chloral hydrate anesthesia, pumps were im-
planted either subcutaneously or intraperitoneally. For subcutane-
ous implantation, a small full-thickness cut was made on the caudal 
side of the dorsum of anesthetized mice and a subcutaneous pouch 
prepared by blunt dissection . The pump was then placed in the 
pouch with the exit port at the cranial end of the pouch. The skin 
was closed with 1 or 2 autoclips (Becton Dickinson, Parsippany, 
NJ) . For intraperitoneal implantation, a full-thickness cut was made 
in abdominal skin to expose the abdominal muscles. A small cut was 
then made through the abdominal muscles and peritoneum, and the 
pump was placed into the peritoneal cavity. The abdominal wall 
was closed with two, 3-0 nylon sutures, and the skin was closed with 
autoclips. 
Light Microscopy Tissue was obtained by tenting an area of skin 
with a small forceps and removing a portion of tissue en bloc with a 
curved iris scissors. Specimens were then fixed in 10% buffered 
formalin and routinely processed. Paraffin embedded tissue sections 
were stained with hematoxylin and eosin: alcian blue (PH 2.5) with 
and without hyaluronidase pretreatment and periodic acid Schiff 
st.ain with and without diastase pretreatment. Staining was as pre-
VIOusly descnbed [34] . Slides were examined in a coded fashion to 
assess changes associated with administration of rMuIFN-y. 
Immunoperoxidase Staining The immunoperoxidase proce-
dures have been previously described in detail [35]. Briefly, 4-.um-
tl~ic~ sec~i~ns for light microscopy were stained in a three-step 
blOtm-avldtn system using the primary antibody, biotinylated 
horse-ant i-mouse (or rabbit) immunoglobulin, and finally 
avidin : biotinylated horseradish peroxidase complexes (Vector Lab-
oratories, Burlingame, CA). The monoclonal antibodies to larninin 
a~d pol~c1onal antibodies to fibronectin were purchased from ICN 
BlOmedlcals, Inc. (Lisle, IN). The sections were stained with 3-
amino-9-ethylcarbazole. 
Transmission Electron Microscopy Small specimens of skin 
were ?btained as above and minced into approximately 1 mm cubes, 
fixed m Karnovsky's II solution for 5 h, and rinsed in 0.1 M sodium 
cacodylate buffer (PH 7.4) for 2 h. Post-fixation was achieved with 
2% osmium tetroxide for 2 h. After 2, 15-min rinses with 0.1 M 
sodium cacodylate buffer, the tissue was dehydrated in graded eth-
anol solutions and embedded in an Epon-Araldite mixture. Ul-
tra~hin se~tions were subsequently cut for electron microscopy, 
stamed With uranyl acetate and lead citrate, and examined with a 
Zeiss EM109 electron microscope (Oberkochen, West Germany) . 
Computerized image analysis of randomly selected cellular fields 
was performed as previously described [36,37] . 
Scoring of Healing Rates Mice were examined in a coded fash-
ion daily after wounding. Each individual wound was scored as 
being co~pletely healed on the day that the lesion was completely 
closed WIth normal epidermis overlying scar tissue and no evident 
crusting. 
T~ermal Camera Measurements The spatial distribution of 
skm surface temperatures around the laser-induced lesions was 
monitored by a thermal camera (Model 600, lnframetrics, Bedford, 
MA). This camera uses a Hg-Cd-Te detector cooled by liquid nitro-
gen to image infrared radiation emitted from a tissue surface in the 
spectral wavelength range of 6 - 10 .urn. The calibrated system 
offers resolution to within 0.1 ° C. 
Induction of Inflammation Mice were injected in the left hind 
footpad with the indicated inflammatory substance in 0.05 ml of 
PBS. Four hours later mice were killed and footpad skin and subcu-
taneous tissue processed for light microscopy. Infiltrating neutro-
phils were quantified by counting cells in four cellular areas of each 
slide in a coded fashion using an ocular grid. 
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Statistical Analysis The significance of differences in times to 
complete healing in neutrophil infiltrates between groups and in 
various parameters examined by quantitative image analysis was 
assessed by the Student's t-test. 
RESULTS 
Characteristics of Wounds Induced by the Argon Laser Ex-
posure of murine skin to the argon laser resulted in an immediate 
change in the color and texture of the irradiated site. Histologically, 
this corresponded to full-thickness coagulative necrosis of the epi-
dermis, dermis, subcutaneous fat, and muscle of the panniculus car-
nosus, changes consistent with a thermal burn (Fig 1). At about 48 h 
after wounding, a zone of erythema developed around each lesion 
(Fig 2B). Erythema increased in intensity for 24- 72 h and then 
faded. Histologic examination of lesions, obtained 48 h after laser 
exposure, showed vasodilitation, congestion and extravasation of 
erythrocytes (Fig 3A), and a pronounced polymorphonuclear infil-
trate adjacent to the necrotic areas. Samples from two separate mice 
from each time point were also obtained on days 4, 6, 8, 10, 12, and 
14 after wounding and processed for light microscopy. From day 2 
to day 6, an increase in the acute in1lammatory infiltrate in the 
perilesional skin was observed (Table I) with progressive margina-
tion of the necrotic epidermis by polymorphonuclear leukocytes 
followed by reepithelialization beneath the eschar. In concert with 
these changes there was progressive pyknosis and involution of the 
necrotic skeletal muscle in association with an acute in1lammatory 
infiltrate. By day 10, residual necrotic subcutaneous fat and muscle 
was replaced by dense granulation tissue containing numerous fi-
broblasts. Fine fibrillar collagen along with scattered polymorpho-
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Figure 1. Mouse skin 48 h after irradiation with argon laser exhibiting a 
focus of coagulative necrosis of the epidermis, dermis, subcutaneous fat. and 
panniculus carnosus (X 31). 
Figure 2. Appearance of lesions 48 h after laser exposure. A : Lesion on mouse implanted with rMulFN-y-loaded pump. B: Lesion on mouse implanted with 
control pump. Note significant perilesional erythema on control animal (arrow). 
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Figure J. Mouse skin 48 h after irradiation. A : Specimen from mouse implanted with control pump. Perilesional skin with dilated blood vessels filled with 
erythrocytes and a dermal and subcutaneous infiltrate composed predominantly of polymorphonuclear leukocytes (X 79). B: Specimen from mouse implanted 
with rMuIFN-y-loaded pump. In the perilesional skin there are dilated blood vessels containing erytnrocytes and a sparse dermal and subcutaneous infiltrate of 
polymorphonuclear leukocytes. Note the significant reduction in the cellular infiltrate and that the blood vessels are less dilated than the control specimen 
(X79) . 
nuclear and mononuclear leukocytes were present. At this time, 
reepithelialization and sloughing of th~ eschar was complete in 
some areas. By 14 d, epidermal regeneration was complete aJ?d cov-
ered a cellular scar that contained collagen bundles predommantly 
oriented parallel to the skin surface. The number of blood :-ressels 
and inflammatory cells had decreased as ~ell. The scar occupied the 
entire th ickness of the skin and was deVOid of adnexal structures, fat, 
or panniculus carnosus. 
Effects of the Continuous Administration of rMuIFN-Y on 
Erythema and Skin Temperature at Wound Sites One hour 
after exposure to the argon laser, C~FI mice were divide? into two 
groups. Osmotic pumps loaded With r~uIFN-y .to deliver 8.7 X 
103 U /h were implanted subcutaneous.ly 111 the mice of one ~rou~, 
while animals in the other group received pumps loaded With di-
luent alone. It was apparent that animals receiving rMulFN-y h~d 
much less perilesional erythema at 48 h co~pared to. c.ontrols (Fig 
2A,B). By gross observatio~, a.ll cont~ol am~als exhlblte? m~rked 
perilesional erythema at thiS time P01l1t, whIle only a mmo.nty ~f 
treated animals exhibited even subtle erythema. Erythema 111 aru-
mals treated with rMuIFN-y subsequently developed at 72 to 96 h, 
but never reached the intensity of that seen earlier in .control a~­
mals. To obtain a quantitative measurem~nt of the dtfferences m 
blood flow between the perilesional areas 111 these two .groups, th.e 
surface temperature of lesional areas (area of coagulative necrosIs 
Table I. Acute Inflammatory Infiltrate in Healing Wounds 







2+.1 - 2+.3+ 





1- 2+.2 - 3+.3+ 
4+.3+.3+ 
2+,1 - 2+ 
. ., d . d 't I"ser exposure as shown. N = 3 for all 
• Lesions were b,OPS'C on vanous ays aTI cr .. 
groups except day 10 groups where N - 2. ., '1 I 
b Biopsies were taken from mice implanted with pumps contalll~ng dl uent a one. 
, Biopsies were t.ken from mice implanted With pumps cont.mmg rMuIFN-Y· 
plus perilesional erythema) was compared with surrounding skin at 
48 h by use of a thermal camera. The lesional areas were all cooler 
than the surrounding skin. a finding consistent with a loss of blood 
supply due to coagulative necrosis. However, the decrease in tem-
perature in lesional areas compared to surrounding skin was less in 
control mice than in rMuIFN-y-treated mice [0.7°C ± 0.1(SEM) 
versus 1.3°C ± 0.1, P < 0.01]. This corresponds to the differences 
seen in perilesional erythema and, presumably, relates to perile-
sional blood flow. The thermal camera was unable to discriminate 
between the area of coagulative necrosis and the adjacent vascular 
response. 
Biopsies of the heal ing wounds and perilesional areas were taken 
from at least two mice in each group on days 2, 4, 6. 8. 10. 12, and 14 
and processed for histologic examination. By visual inspection, 
most remaining lesions were healed by 14 d. Considerable acute 
inflammation was present histologically in the specimens from days 
2 - 10. The amount of acute inflammatory infiltrate was semi-quan-
tified on a 0 to 4+ scale in a coded fashion by one dermatopatholo-
gist (RJM) as follows: 0: no cells; 1+: margination of polymorpho-
nuclear cells in vessels with a small number outside of vessels; 2+: 
large number of cells between collagen bundles at edge of wound; 
3+: large number of cells between collagen bundles at edge of 
wound with influx into subadjacent areas; 4+: sheets of polymor-
phonuclear cells throughout wound edges and subadjacent areas. 
Table 1 displays the scores of slides in each group. As shown, 
specimens from IFN-y-treated animals generally contained less 
acute inflammation than control specimens on days 2, 4, and 6. This 
difference was lost by day 8. Specimens from control animals ob-
tained on day 2 appeared. subjectively, to contain a greater degree of 
vasodilitation and erythrocyte congestion of vessels in perilesional 
areas than did samples from treated mice (Fig 3A,B), although varia-
tion from place to place within histologic sections was present. This 
finding was consistent with the differences in perilesional erythema 
and lesional temperature discussed above. 
IFN-y Decreases Collagen and Increases Hyaluronate in 
Healing Scars Specimens obtained on days 10. 12, and 14 from 
animals that received rMuIFN-y had a decreased amount of fibrillar 
collagen in the healing scars compared to controls (similar to Fig 4; 
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Figure 4. Lesional skin 14 d after irradiation. A: Specimen from mouse 
implanted with control pump. A scar composed of spindle-shaped fibroblasts 
and horizontally oriented collagen bundles with scant interstitial edema 
(X 500). B: Specimen from mouse implanted with rMuIFN-y-loaded pump. 
Epithelioid-shaped fibroblasts and scattered thin collagen bundles (X 500). 
C: Specimen from mouse implanted with pump loaded with heat-treated 
(80·C for 30 min) rMuIFN-y. Findings similar to those seen in A (X 500). 
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Table n. Staining for Mucopolysaccharides 
Stain' 
Alcian Blue 
Alcian Blue plus 
Hyaluronidase 
Periodic Acid Schiff 
Periodic Acid Schiff 
plus Diastase 
Control 
1 +.1 +.0-1+ 
0,0,0 
3+,2+.3+ 





























• Histologic sections were stained as shown. The number of specimens examined in each group is as shown. 
b Specimens were taken from animals with pumps implanted subcutaneously. 
, Specimens were taken from animals with pumps implanted intra peritoneally. 
see below). In particular. fibers were of greatly reduced diameter 
and were decreased in density over the surface area of microscopic 
sections as compared to controls. 
Since specimens from IFN-y-treated mice had increased space 
between collagen fibers. sections were stained with alcian blue (pH 
2.5) with and without pretreatment with hyaluronidase as well as 
with periodic acid-Schiff (PAS) stains with and without pretreat-
ment with diastase. Sections were examined in a coded fashion by a 
dermatopathologist (RJM) and semi-quantified on a 0 to 4+ scale as 
follows: 0: no staining; 1 +: very small amount of focal staining; 2+: 
scattered small areas of focal staining; 3+: multiple large areas of 
staining; 4+: staining throughout the scar tissue. 
As shown in Table II, at the three time points examined, speci-
mens from IFN-y-treated mice contained more alcian blue-staining 
material than specimens from control animals. Thus. specimens 
from IFN-y-treated contain more acid mucopolysaccharide (AMPS) 
than control specimens. Furthermore, since pretreatment with hy-
aluronidase abolished the staining. hyaluronic acid accounted for 
most of the additional AMPS. PAS-positive material was found in 
specimens from both IFN-y-treated and control mice as well. Al-
though a trend to heavier staining in control specimens compared to 
specimens from IFN-y-treated mice was noted, the magnitude of 
the difference was small; thus. no conclusion can be drawn. Diastase 
pretreatment removed a significant portion of the staining in all 
groups; thus, much of the PAS staining was due to glycogen. 
A similar experiment was performed in which three groups of 
CAF, mice were examined. Mice received pumps loaded with 
rMuIFN-y, heat-treated rMuIFN-y (80·C for 30 min) . or diluent 
alone. Exposure to 80·C for 30 min inactivates IFN-y [38]. As in 
the previous experiment. a decrease in perilesional erythema was 
seen in the animals that received rMuIFN-y compared to the other 
groups. Histologic sections of dermal scars 14 d after laser exposure 
from each of the three groups are shown in Fig 4A -C. Note that 
scars from animals that received rMuIFN-y contained less fibrous 
material and that the fibers were oflesser thickness compared to scar 
tissue from animals that received inactivated rMuIFN-y or diluent 
alone. Staining of sections from this experiment with alcian blue 
gave results similar to those shown in Table II; specimens from mice 
treated with heat-treated rMuIFN-ywere identical to control speci-
mens. 
Examination for Laminin and Fibronectin by Immunoper-
oxidase The amount of laminin and fibronectin present in frozen 
sections of scars obtained 10. 12, and 14 d after treatment with 
gamma interferon or control media was evaluated using monoclo-
nal antibodies in a three-step immunoperoxidase technique. Lami-
nin was present in the basement membrane zone of normal adjacent 
skin. adnexal structures. and blood vessels. On day 10, in control 
and rMuIFN-y treated mice. the laminin staining of the basement 
membrane zone of the skin and blood vessels in the area of the scars 
showed variable expression ranging from slight to significant. On 
subsequent days, the staining in both areas was strong. There were 
no significant differences in the staining patterns or intensities be-
tween the control and rMuIFN-y treated specimens. Negative con-
trols without primary antibody showed no staining. 
Fibronectin was present in the basement membrane zone of nor-
mal adjacent skin and adnexal structures. In addition, there was 
staining of the extracellular matrix region which was accentuated 
around the collagen fibers. In scars obtained on days 10, 12, and 14 
there was increased staining for fibronectin in the basement mem-
brane zone of the skin overlying the scars relative to the normal 
adjacent skin. No increased staining of the extracellular matrix re-
gions was appreciated. The negative control slides showed no stain-
ing. There were no significant differences between the staining 
pattern or intensities of the control or rMuIFN-y treated animals. 
Electron Microscopy Transmission electron microscopy was 
performed on specimens from day 14 and. in a separate experiment, 
day 21 (7 d after the pumps were exhausted). The findings were 
similar at each time point. The scar tissue in the area of the wound 
from rMuIFN-y-treated mice contained less collagen as compared 
with scar tissue from the control group. The quantity of collagen as 
determined by the percent area containing collagen in electron mi-
crographs was 42.2% ± 1.6 (SEM) and 37.8% ± 4.2 for the 
rMuIFN-y treated animals and 66.5% ± 1.4 (p < 0.01) and 
63.7% ± 5.5 (p < .03) for the control animals at days 14 and 21, 
respectively, as determined by quantitative image analysis of 
0.03 mm2 areas in eight randomly selected fields per specimen. In 
the rMuIFN-y treated animals. collagen fibers were smaller as com-
pared to the control group (Fig 5A,B). Quantitative image analysis 
of collagen fiber cross-sectional areas was determined at day 21 by 
examination of a total area of 0.04 mm2 in specimens &om each 
group. One-hundred thirty-eight evaluable fibers were examined in 
the treated specimens and 181 in the control specimens. A mean 
fiber cross-sectional area of 9.40 ± 0.48 (SEM) J.I.m2 in wounds of 
mice treated with rMuIFN -y was found as compared to a mean area 
of 21.43 ± 1.02 J.I.m2 in wounds of control animals (p < 0.001). In 
both groups, the fibrils were uniform and of the same size, 145 ± 
1.5 nm and 149 ± 9.5 nm for IFN-y-treated and control mice. re-
spectively. The fibroblasts in the specimens from control animals 
appeared to be larger than the fibroblasts in the specimens from the 
treated group and had more abundant rough endoplasmic reticu-
lum. The size of the fibroblasts (myofibroblasts were excluded) was 
quantitated in day 21 animals by measuring the smallest diameter of 
the cell which included the center of the nucleus. Sixty-seven fibro-
blasts from treated specimens and 70 from control specimens were 
evaluated. The mean diameter of rMuIFN-)'-treated mice was 
2.34 ± 0.13 (SEM) J.l.m as compared to 3.39 ± 0.15 J.I.m for the con-
trol mice (p < 0.001). 
Effects of Implanting Osmotic Pumps Intraperitoneally In 
the experiments cited above. pum.ps were implanted subcutaneously 
at a site distant from the lesions. We performed additional experi-
ments, however, in which pumps were implanted intraperitoneally 
in order to confirm that the changes observed were due to a systemic 
rather than a local effect of rMuIFN-y. Results similar to those 
observed with subcutaneous pumps were obtained with intraperito-
neal implantation in AI] mice. Decreased perilesional erythema was 
again observed at 48 h in mice receiving rMuIFN-y as compared to 
the control group. Light and electron microscopic examination of 
scar tissue of healed lesions obtained from both groups on days 14, 
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Figure S. Electron micrographs from day 21 . A: Dermis of control animal. Note the fibroblasts (F) with abundant rough endoplasmic reticulum and the size 
of the collagen fibers and fibrils asterisk (Bar: 5 tim). B: Dermis of rMuIFN-Y treated animal. Note the fibroblasts (F) with less abundant rough endoplasmic 
reticulum and the smaller collagen fibrils (asterisk) as compared to the control (Bar: 5 Jim) . 
IS, and 21 yielded results similar or identical to those described 
above for experiments with subcutaneously implanted pumps. Fig-
ure 6A,B shows the results of light microscopy of specimens from 
control and IFN-y-treated mice on day 21. Quantitative image anal-
ysis of 0.03 mm2 areas in eight randomly selected fields per speci-
men revealed the percent area containing coHagen in electron mi-
crographs to be 22.0% ± 2.7 (SEM) for the rMuIFN-y-treated 
animals and 32.7% ± 2.1 (p < 0.01) for the control animals at day 
21. These numbers are not directly comparable to the image analysis 
values given for the experiments in which pumps were implanted 
subcutaneously, because in this experiment electron microscopy 
was performed on deparaflinized tissue originaHy fixed for light 
microscopy, while the earlier values were obtained from tissue fixed 
for electron microscopy. 
Effects of rMuIFN-y on Time to Healing of Wounds In the 
experiments described above a trend to earlier healing of lesions in 
control mice compared with IFN-y-treated mice was casually ob-
served. Therefore, the time to healing in subsequent experiments 
utilizing subcutaneous and intraperitonal pumps was scored daily by 
one observer in a coded fashion. As shown in Table Ill, the time to 
healing scored by the day of complete epithelialization was signifi-
cantly prolonged in the groups that received rMuIFN-y compared 
to mice that received inactivated rMuIFN-y or diluent alone. 
rMuIFN-y Decreases the Local Acute Inflammatory Re-
sponse to Pro-Inflammatory Agents In order to further evalu-
ate the anti-inflammatory effect of rMuIFN-y observed at the sites 
of skin wounding, we examined the ability of rMulFN-y to inhibit 
acute inflammation induced by known inflammatory stimuli. The 
injection of interleukin 1 (Il-l) into the mouse footpad results in 
the accumulation of neutrophils locally with a peak accumulation at 
4 h [39]. Similar experiments were performed in mice receiving 
IFN-y. Three AI] mice received intraperitoneal pumps that deliv-
ered 8.7 X 103 U/h of rMuIFN-y and three received pumps con-
taining diluent alone. Forty-eight hours later, the left hind footpad 
of each mouse was injected with 50 units of rHull-1o: in 50 J.lI PBS. 
Four hours later, all mice were killed and footpad tissue was pro-
cessed for routine light microscopy. Using an ocular grid, four 
0.14 mm2 cellular areas of each specimen were examined in a coded 
fashion, and polymorphonuclear cells were quantified. The mean 
number of cells in the rMuIFN-y-treated group was found to be 566 
ceHs/mm2 ± 123 (SEM) compared to 1612 ± 329 (p < 0.05) in the 
diluent group. In an additional experiment a 1 : 2 dilution of acti-
vated serum was employed in a similar manner except that only 
5 X 103 units of rMuIFN-y were delivered per hour by each pump. 
The mean number of cells in the rMuIFN-y-treated groups was 
915 ± 363 (SEM), compared to 2729 ± 529 (p < 0.05) in the di-
luent group. Similar results were obtained when rMulFN-y was 
given to mice by intraperitoneal injections at 48, 24, and 1 h prior to 
injection of the inflammatory stimulus. 
DISCUSSION 
The presence of various inflammatory and immunocompetent cells 
in fibrous tissue undergoing repair processes, pathologic fibrosis, or 
degradation [40 -42] has supported the hypothesis that cytokines 
may participate in the regulation of fibrous tissue turnover. We and 
others have previously demonstrated that IFN-y decreases collagen 
[17 - 22] and fibronectin [18] synthesis, while 1l-1 increases colla-
gen and fibronectin synthesis in vitro [14,15]. In addition, IFN-y 
inhibits the in vivo formation of fibrous capsules around implanted 
osmotic pumps [23]. As presented in this study, systemically admin-
istered IFN-y down-regulated the synthesis of collagen in healing 
skin wounds. Associated with the decrease in collagen in wound 
scars was an increase in AMPS content, primarily hyaluronic acid. 
The demonstration that the biologic activity attributable to IFN-y 
was heat-labile correlates with the previously described loss of other 
biologic activities by heat treatment of IFN-y [38]. We did not 
detect an effect ofIFN-y on the appearance oflaminin or fibronectin 
in the healing wounds by antibody staining. The immunoperoxi-
dase technique, however, is not quantitative and it may be difficult 
to appreciate differences in laminin or fibronectin content by this 
method. 
of particular interest was the observation that systemically ad-
ministered IFN-y decreased acute inflammation as determined by 
decreased perilesional erythema, temperature, and acute inflamma-
tory cell infiltrate. In addition to its effects on burn injuries, we 
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Figure 6. Scar tissue 21 d after laser injury. A : Specimen from mouse implanted with control pump. A scar composed of spindle-shaped fibroblasts and thick 
horizontally oriented collagen bundles (X 500). B: Specimens from mouse implanted with rMuIFN-y-loaded pump. Note smaller and less distinct collagen 
bundles (X 500). 
found that rMulFN-y inhibited the acute inflammatory response to 
cutaneous injections of two pro-inflammatory agents, rHulL-Ia, 
and activated serum. Indeed, in preliminary studies, IFN-y signifi-
cantly reduced radiation-induced pulmonary inflammation in rats as 
assessed by recovery of cells and protein in whole lung lavage and 
histologic eva luation of lung tissues [43]. This anti-inflammatory 
activity of IFN-y is consistent with a recent report that systemically 
administered IFN-y down-regulates tissue swelling in response to 
lipopolysaccharide when injected into footpads [441. 
lFN-y has been demonstrated to have a number o( activities by in 
vitro assays that are consistent with the notion that IFN-y would 
promote inflammatory cell entry into sites of inflammation in vivo. 
These biologic effects include increasing intercellular adhesion 
molecule-l (ICAM-l) expression by and adherence oflymphocytes 
to endothelial cells [45] as well as alterations in the morphology of 
vascular endothelium [46] . Furthermore, IFN-y increases binding 
of peripheral blood mononuclear leukocytes (PBML) and, to a lesser 
degree, neutrophils to keratinocytes [47]. Lymphocyte binding is 
blocked by antibodies to lymphocyte function-associated antigen-l 
(LFA-l) [47]. Nonetheless, under the conditions of our study, 
IFN-y reduced several parameters of inflammation in vivo, includ-
ing erythema, temperature, and neutrophil influx. A host of media-
tors are involved in the expression of inflammation [48] and the in 
vivo experiments reported here were not designed to determine the 
mechanism of action of lFN-y in this regard. A recent report that 
IFN-y has trophic effects on skin microvascular endothelial cells 
Table m. IFN-y Alters Healing of Cutaneous Wounds 
Mean Time to Healing 
Group' Pump Contentsb (Days ± SEM)c p Valued 
Experiment 1 
1 Diluent 11.3 ± 0.6 
2 Heat-treated rMuINF-y< 11.6 ± 0.4 NS 
3 rMuIFN-y 14.3 ± 0.8 <0.05 
Experiment 2 
1 Diluent 11.6 ± 0.4 
2 rMuIFN-y 14.8 ± 0.4 <0.0 1 
• Experiment 1: Four lesions on 2 CAFI mice in group I , live lesions on two mice in group 2. four lesions on two mice in group 3. Experiment 2: Twenty-seven lesions on seven 
mice in group 1 and 16 lesions on live mice in group 2. 
b In Experiment 1 pumps were implanted subcutaneously. In Experiment 2 pump' wore implanted intraperitoneally. 
, Time to complete epIthelialization without any romaining crUSt. 
d ompared to group 1. 
, rMulFN-l' was heated to 80'C for 30 min. 
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may relate to our observation of decreased accumulation of neutro-
phils at inflammatory sites in IFN-y-treated mice [49]. Indeed, the 
possible anti-inflammatory effects of IFN-y may be relevant to the 
recent reports that IFN-y may be useful therapeutically in the treat-
ment of patients with rheumatoid arthritis [50 - 53]. 
We also found that the mean time to wound closure was delayed 
in mice treated with rMuIFN-y. Because this cytokine displays anti-
proliferative activity for a variery of cell types in vitro, including 
keratinocytes (54,55), this observation might reflect inhibition of 
keratinocyte proliferation in vivo. 
The sensitivity of IFN-y to heat also rules out the possibility that 
endotoxin contamination is responsible for these results; endotoxin 
is not affected by heating to 80°C for 30 min [56] . 
The mechanism by which collagen synthesis is inhibited by 
IFN-y cannot be assessed in these types of in vivo experiments, 
although presumably it relates to the inhibition of collagen mRNA 
synthesis seen in in vitro experiments [21-22]. IFN-y directly de-
creases the synthesis of collagen and fibronectin by fibroblasts in 
vitro in the absence of other cell types. Whether the increase in 
AMPS observed results from a direct effect of IFN-y on fibroblasts 
or an indirect effect requiring cellular interactions cannot be ascer-
tained from our experiments. 
With these results we extend our previous findings to demon-
strate that systemic administration of IFN-y inhibits collagen syn-
thesis in vivo in a skin wound healing model; thus, the level of 
IFN-y present at distant sites is sufficient to influence new collagen 
synthesis. 
Numerous disease states, including keloids, hypertrophic scars, 
scleroderma, morphea, and graft-versus-host disease, among many 
others, are characterized in part by pathologic fibrosis of the skin. 
One may speculate that the pathogenesis of some of these disorders 
may be due, in part, to abnormal regulation or response to cytokines 
or other modulators involved in matrix turnover. These studies lend 
further support to the concept that, should adverse side effects prove 
acceptable, IFN-y might be useful in the therapy of some of these 
diseases and may raise the possibility of impaired wound healing in 
patients receiving long-term therapy with IFN-y. 
In addition, examination of the effects of IFN-y on cutaneous 
thermal injuries permitted us to observe the ability of IFN-y to 
modulate acute inflammation. Further studies are required to define 
the mechanisms by which IFN-y modulates neutrophil influx to 
inflammatory sites in vivo. 
We thattk Dr. Thomas Deutsch for helpful suggestions and Ms. Dia,t! Dalton and 
Ms. Amy Stoddard for preparatiotl of this matluscript. 
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